相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Antibodies to watch in 2016
Janice M. Reichert
MABS (2016)
Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer
E. Elez et al.
BRITISH JOURNAL OF CANCER (2016)
Necitumumab: First Global Approval
Karly P. Garnock-Jones
DRUGS (2016)
Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display
Philipp Kuhn et al.
PROTEOMICS CLINICAL APPLICATIONS (2016)
Structural differences of amyloid-β fibrils revealed by antibodies from phage display
Patrick Droste et al.
BMC BIOTECHNOLOGY (2015)
Generation and analysis of the improved human HAL9/10 antibody phage display libraries
Jonas Kuegler et al.
BMC BIOTECHNOLOGY (2015)
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
Nick Thatcher et al.
LANCET ONCOLOGY (2015)
Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B
Christine Rasetti-Escargueil et al.
MABS (2015)
Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery
Chiara Romani et al.
ONCOTARGET (2015)
The prevention and management of rabies
Natasha S. Crowcroft et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
The prevention and management of rabies
Natasha S. Crowcroft et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial
Frank Behrens et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Antibodies to watch in 2015
Janice M. Reichert
MABS (2015)
The therapeutic monoclonal antibody market
Dawn M. Ecker et al.
MABS (2015)
Development of Human-Like scFv-Fc Neutralizing Botulinum Neurotoxin E
Sebastian Miethe et al.
PLOS ONE (2015)
Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study
Michael Schiff et al.
RMD OPEN (2015)
Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis
Cris S. Constantinescu et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2015)
Management of acute attacks of hereditary angioedema: role of ecallantide
Hannah Duffey et al.
JOURNAL OF BLOOD MEDICINE (2015)
A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma
Chuanying Geng et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
A phase 1 study investigating DX-2930 in healthy subjects
Yung Chyung et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2014)
The efficacy of novel B cell biologics as the future of SLE treatment: A review
Ameer Kamal et al.
AUTOIMMUNITY REVIEWS (2014)
Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice
Aline Frazier-Mironer et al.
JOINT BONE SPINE (2014)
Inhibition of Plasma Kallikrein by a Highly Specific Active Site Blocking Antibody
Jon A. Kenniston et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs et al.
LANCET (2014)
Systemic lupus erythematosus
Larissa Lisnevskaia et al.
LANCET (2014)
Antibodies to watch in 2014
Janice M. Reichert
MABS (2014)
The influence of antibody fragment format on phage display based affinity maturation of IgG
Miriam Steinwand et al.
MABS (2014)
Drugs derived from phage display From candidate identification to clinical practice
Andrew E. Nixon et al.
MABS (2014)
Human- like antibodies neutralizing Western equine encephalitis virus
Birgit Huelseweh et al.
MABS (2014)
Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library
Sebastian Miethe et al.
MABS (2014)
Phage display and hybridoma generation of antibodies to human CXCR2 yields antibodies with distinct mechanisms and epitopes
Christine J. Rossant et al.
MABS (2014)
Functional Characterization of Two scFv-Fc Antibodies from an HIV Controller Selected on Soluble HIV-1 Env Complexes: A Neutralizing V3-and a Trimer-Specific gp41 Antibody
Maria Trott et al.
PLOS ONE (2014)
Anthrax lethal and edema toxins in anthrax pathogenesis
Shihui Liu et al.
TRENDS IN MICROBIOLOGY (2014)
Raxibacumab: potential role in the treatment of inhalational anthrax
Carlos E. Kummerfeldt
INFECTION AND DRUG RESISTANCE (2014)
Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Construction and characterization of functional anti-epiregulin humanized monoclonal antibodies
Young-Hun Lee et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells
Volker Jaeger et al.
BMC BIOTECHNOLOGY (2013)
Critical Appraisal of Ramucirumab (IMC-1121B) for Cancer Treatment: From Benchside to Clinical Use
Giuseppe Aprile et al.
DRUGS (2013)
Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library
Mingkui Zhou et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2013)
Human antibody expression in transgenic rats: Comparison of chimeric IgH loci with human VH, D and JH but bearing different rat C-gene regions
Biao Ma et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2013)
Discovery of diverse and functional antibodies from large human repertoire antibody libraries
Lauren J. Schwimmer et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2013)
Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study
William Stohl et al.
JOURNAL OF RHEUMATOLOGY (2013)
A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties
Thomas Tiller et al.
MABS (2013)
Which are the antibodies to watch in 2013?
Janice M. Reichert
MABS (2013)
Phase I Trial and Pharmacokinetic Study of Lexatumumab in Pediatric Patients With Solid Tumors
Melinda S. Merchant et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The discovery and development of belimumab: the anti-BLyS-lupus connection
William Stohl et al.
NATURE BIOTECHNOLOGY (2012)
Isolation and Characterisation of a Human-Like Antibody Fragment (scFv) That Inactivates VEEV In Vitro and In Vivo
Torsten Ruelker et al.
PLOS ONE (2012)
Dacarbazine and the Agonistic TRAIL Receptor-2 Antibody Lexatumumab Induce Synergistic Anticancer Effects in Melanoma
Birgit Engesaeter et al.
PLOS ONE (2012)
Bortezomib Combination Therapy in Multiple Myeloma
Prashant Kapoor et al.
SEMINARS IN HEMATOLOGY (2012)
Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development
Andrew D. Cook et al.
ARTHRITIS RESEARCH & THERAPY (2012)
The role of vaccination in rabies prevention
Deborah J. Briggs
CURRENT OPINION IN VIROLOGY (2012)
Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
The therapeutic potential of TRAIL receptor signalling in cancer cells
Rosario Yerbes et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2011)
A human scFv antibody generation pipeline for proteome research
Michael Hust et al.
JOURNAL OF BIOTECHNOLOGY (2011)
Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non-Small-Cell Lung Cancer
Jean-Charles Soria et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
HuCAL PLATINUM, a Synthetic Fab Library Optimized for Sequence Diversity and Superior Performance in Mammalian Expression Systems
Josef Prassler et al.
JOURNAL OF MOLECULAR BIOLOGY (2011)
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V. Navarra et al.
LANCET (2011)
Antibodies for biodefense
Jeffrey W. Froude et al.
MABS (2011)
Beyond natural antibodies: the power of in vitro display technologies
Andrew R. M. Bradbury et al.
NATURE BIOTECHNOLOGY (2011)
Myositis Ossificans
Deborah A. Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rise and Fall of an Anti-MUC1 Specific Antibody
Holger Thie et al.
PLOS ONE (2011)
Cytokine disturbances in systemic lupus erythematosus
Noam Jacob et al.
ARTHRITIS RESEARCH & THERAPY (2011)
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
A. Younes et al.
BRITISH JOURNAL OF CANCER (2010)
Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
T. Trarbach et al.
BRITISH JOURNAL OF CANCER (2010)
A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies
D. Ross Camidge et al.
CLINICAL CANCER RESEARCH (2010)
Acceptability of switching adalimumab from a prefilled syringe to an autoiniection pen
Joaquin Borras-Blasco et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
Selection of full-length IgGs by tandem display on filamentous phage particles and Escherichia coli fluorescence-activated cell sorting screening
Yariv Mazor et al.
FEBS JOURNAL (2010)
An improved manufacturing process for Xyntha/ReFacto AF
B. Kelley et al.
HAEMOPHILIA (2010)
Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
Jennifer L. Spratlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Development trends for human monoclonal antibody therapeutics
Aaron L. Nelson et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Ecallantide
Bruce Zuraw et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Generating recombinant antibodies to the complete human proteome
Stefan Duebel et al.
TRENDS IN BIOTECHNOLOGY (2010)
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Belimumab in Patients With Active Systemic Lupus Erythematosus
Daniel J. Wallace et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor Current Status and Future Challenges in Cancer Therapy
Jerry Y. Hsu et al.
BIODRUGS (2009)
Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study
Constantijne H. Mom et al.
CLINICAL CANCER RESEARCH (2009)
Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor
Zehra Kaymakcalan et al.
CLINICAL IMMUNOLOGY (2009)
Interaction of antibodies with ErbB receptor extracellular regions
Karl R. Schmitz et al.
EXPERIMENTAL CELL RESEARCH (2009)
Accelerated Pathological and Clinical Nephritis in Systemic Lupus Erythematosus-Prone New Zealand Mixed 2328 Mice Doubly Deficient in TNF Receptor 1 and TNF Receptor 2 via a Th17-Associated Pathway
Noam Jacob et al.
JOURNAL OF IMMUNOLOGY (2009)
The Role of IL-23/IL-17 Axis in Lupus Nephritis
Zheng Zhang et al.
JOURNAL OF IMMUNOLOGY (2009)
Obtention and Engineering of Non-Human Primate (NHP) Antibodies for Therapeutics
Thibaut Pelat et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2009)
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals
Johannes F. Scheid et al.
NATURE (2009)
Identification of a Putative Crf Splice Variant and Generation of Recombinant Antibodies for the Specific Detection of Aspergillus fumigatus
Mark Schuette et al.
PLOS ONE (2009)
Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire
Jacob Glanville et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens
C. Lloyd et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2009)
Camelid immunoglobulins and nanobody technology
S. Muyldermans et al.
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY (2009)
Epidermal growth factor receptor immunohistochemistry - Comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer
Fred R. Hirsch et al.
CANCER (2008)
Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5
C. Adams et al.
CELL DEATH AND DIFFERENTIATION (2008)
A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies
Sebastien J. Hotte et al.
CLINICAL CANCER RESEARCH (2008)
Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery
Andreas Lehmann
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies
Christine Rothe et al.
JOURNAL OF MOLECULAR BIOLOGY (2008)
In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification
Stefan Steidl et al.
MOLECULAR IMMUNOLOGY (2008)
Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer
F. Anthony Greco et al.
LUNG CANCER (2008)
Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8
Shiqing Li et al.
STRUCTURE (2008)
First administration to humans of a monoclonal antibody cocktail against rabies virus: Safety, tolerability, and neutralizing activity
A. B. H. Bakker et al.
VACCINE (2008)
Colony-stimulating factors in inflammation and autoimmunity
John A. Hamilton
NATURE REVIEWS IMMUNOLOGY (2008)
Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition
Katherine Holmes et al.
CELLULAR SIGNALLING (2007)
High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation
Thibaut Pelat et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors
A. W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Vascular endothelial growth factor (VEGF) signaling in tumor progression
Robert Roskoski
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1
Anthony W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Infections during tumour necrosis factor-α blocker therapy for rheumatic diseases in daily practice:: a systematic retrospective study of 709 patients
C. Salliot et al.
RHEUMATOLOGY (2007)
A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF
Eva-Maria Krinner et al.
MOLECULAR IMMUNOLOGY (2007)
On the influence of vector design on antibody phage display
Glenn Soltes et al.
JOURNAL OF BIOTECHNOLOGY (2007)
Application of phage display to high throughput antibody generation and characterization
Darren J. Schofield et al.
GENOME BIOLOGY (2007)
Recombinant therapeutic antibodies
Stefan Duebel
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2007)
A highly stable polyethylene glycol-conjugated human single-chain antibody neutralizing granulocyte-macrophage colony stimulating factor at low nanomolar concentration
Eva-Maria Krinner et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2006)
The epidermal growth factor receptor pathway: A model for targeted therapy
Maurizio Scaltriti et al.
CLINICAL CANCER RESEARCH (2006)
Engineering of therapeutic antibodies to minimize immunogenicity and optimize function
Leonard G. Presta
ADVANCED DRUG DELIVERY REVIEWS (2006)
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis
M. H. Schiff et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2
Hua-Quan Miao et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: Pharmacokinetic, pharmacodynamic, and toxicologic effects
Wendy G. Halpern et al.
TOXICOLOGICAL SCIENCES (2006)
Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin
J Goudsmit et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF
WC Liang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants
ABH Bakker et al.
JOURNAL OF VIROLOGY (2005)
The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries
RA Kramer et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
BAFF augments certain Th1-associated inflammatory responses
APR Sutherland et al.
JOURNAL OF IMMUNOLOGY (2005)
From rodent reagents to human therapeutics using antibody guided selection
J Osbourn et al.
METHODS (2005)
The ErbB receptors and their ligands in cancer: An overview
N Normanno et al.
CURRENT DRUG TARGETS (2005)
Immunogenicity of engineered antibodies
WYK Hwang et al.
METHODS (2005)
HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo
L Pukac et al.
BRITISH JOURNAL OF CANCER (2005)
Vascular endothelial growth factor(VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and-2 heterodimer
PE Neagoe et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity
RM Hoet et al.
NATURE BIOTECHNOLOGY (2005)
Vascular endothelial growth factor: Basic science and clinical progress
N Ferrara
ENDOCRINE REVIEWS (2004)
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β
B Bielekova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab1)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels
EA Panacek et al.
CRITICAL CARE MEDICINE (2004)
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2
J Oliner et al.
CANCER CELL (2004)
Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries
T Jostock et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2004)
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed
BA van de Putte et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator
KP Baker et al.
ARTHRITIS AND RHEUMATISM (2003)
Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity
D Lu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Identification of scFv antibody fragments that specifically recognise the heroin metabolite 6-monoacetylmorphine but not morphine
A Moghaddam et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2003)
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study
MH Weisman et al.
CLINICAL THERAPEUTICS (2003)
Recombinant antibodies to the small GTPase Rab6 as conformation sensors
C Nizak et al.
SCIENCE (2003)
Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate - The ARMADA trial
ME Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2003)
Domain antibodies: proteins for therapy
LJ Holt et al.
TRENDS IN BIOTECHNOLOGY (2003)
The production of a genus-specific recombinant antibody (scFv) using a recombinant potyvirus protease
M Hust et al.
JOURNAL OF VIROLOGICAL METHODS (2002)
VEGF-Trap: A VEGF blocker with potent antitumor effects
J Holash et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Anthrax as a biological weapon, 2002 - Updated recommendations for management
TV Inglesby et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy
D Lu et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Granulocyte macrophage colony-stimulating factor: A new putative therapeutic target in multiple sclerosis
JL McQualter et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Signaling properties of VEGF receptor-1 and-2 homo- and heterodimers
K Huang et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2001)
Local transgenic expression of granulocyte macrophage-colony stimulating factor initiates autoimmunity
M Biondo et al.
JOURNAL OF IMMUNOLOGY (2001)
A helper phage to improve single-chain antibody presentation in phage display
S Rondot et al.
NATURE BIOTECHNOLOGY (2001)
Cutting edge: A role for B lymphocyte stimulator in systemic lupus erythematosus
J Zhang et al.
JOURNAL OF IMMUNOLOGY (2001)
Antibody arrays for high-throughput screening of antibody-antigen interactions
RMT de Wildt et al.
NATURE BIOTECHNOLOGY (2000)
Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries
E Söderlind et al.
NATURE BIOTECHNOLOGY (2000)
Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides
A Knappik et al.
JOURNAL OF MOLECULAR BIOLOGY (2000)
分享论文
